SUNOHARA Mitsuhiro 春原光宏

… Alternative Names

春原光宏スノハラミツヒロ

Sunohara Mitsuhiro 春原光宏

Less

Researcher Number	00637697
Other IDs
Affiliation (Current)	2026: 東京大学, 保健・健康推進本部, 講師
Affiliation (based on the past Project Information) *help	2024: 東京大学, 保健・健康推進本部, 講師 2021 – 2022: 東京大学, 保健・健康推進本部, 講師 2018 – 2020: 東京大学, 保健・健康推進本部, 助教 2012 – 2013: 東京大学, 医学部附属病院, 助教
Review Section/Research Field	Principal Investigator Basic Section 09010:Education-related / Basic Section 09040:Education on school subjects and primary/secondary education-related / Laboratory medicine
Keywords	Principal Investigator 偶発的学習 / ヘルスリテラシー / 高等教育 / 保健 / 青年期 / 大学生 / 質問紙法 / 保健体育 / 尺度開発 / アンケート調査 … More / メディカルリテラシー / 分子標的薬 / がん遺伝子 / 肺がん / vandetanib / lung cancer / RET-proto oncogene / チロシンキナーゼ / 肺癌 / RET Less

Research Projects
(3 results)
Research Products
(12 results)

青少年の医学関連知識・ヘルスリテラシーの向上を目指した介入研究Principal Investigator
- Principal Investigator
  
  春原光宏
- Project Period (FY)
  2024 – 2027
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 09010:Education-related
- Research Institution
  The University of Tokyo
Scale development for medicine-associated knowledge for adolescence and health literacy evaluationPrincipal Investigator
- Principal Investigator
  
  Sunohara Mitsuhiro
- Project Period (FY)
  2018 – 2022
- Research Category
  
  Grant-in-Aid for Early-Career Scientists
- Review Section
  
  Basic Section 09040:Education on school subjects and primary/secondary education-related
- Research Institution
  The University of Tokyo
RET overexpression on lung cancerPrincipal Investigator
- Principal Investigator
  
  SUNOHARA Mitsuhiro
- Project Period (FY)
  2012 – 2013
- Research Category
  
  Grant-in-Aid for Research Activity Start-up
- Research Field
  
  Laboratory medicine
- Research Institution
  The University of Tokyo

All 2022 2014 2012

All Journal Article Presentation

[Journal Article] Abstract B22: Can lung cancer with overexpression of RET-proto oncogene be a good candidate for vandetanib treatment?2014
- Author(s)
  Sunohara M, Morita S, Kawakami M, Watanabe K, Kage H, Amano Y, Ishikawa R, Fukayama M, Nagase T, Ohishi N, and Takai D
- Journal Title
  
  Clin Cancer Res
  
  Volume: 20
- Data Source
  KAKENHI-PROJECT-24890041
[Journal Article] Can lung cancer with overexpression of RET-proto oncogene be a good candidate for vandetanib treatment?2014
- Author(s)
  Mitsuhiro Sunohara, Shigeki Morita, Masanori Kawakami, Kousuke Watanabe, Hidenori Kage, Yousuke Amano, Rie Ishikawa, Masahisa Fukayama, Takahide Nagase, Nobuya Ohishi, and Daiya Takai
- Journal Title
  
  Clin Cancer Res
  
  Volume: 2Suppl Pages: 20-20
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24890041
[Journal Article] Vandetanib Can Overcome the Acquired Resistance to Gefitinib Due to RET Overexpression in Lung Cancer2012
- Author(s)
  M Sunohara
- Journal Title
  
  European Journal of Cancer
  
  Volume: 48 Suppl.6 Pages: 95-95
- DOI
  10.1016/s0959-8049(12)72109-3
- Data Source
  KAKENHI-PROJECT-24890041
[Journal Article] Vandetanib Can Overcome the Acquired Resistance to Gefitinib Due to RET Overexpression in Lung Cancer2012
- Author(s)
  M. Sunohara, M. Kawakami, K. Watanabe, S. Morita, H. Kage, Y. Amano, M. Fukayama, T. Nagase, N. Ohishi, D. Takai
- Journal Title
  
  Eur.J.Cancer. Supp
  
  Volume: 16 Pages: 95-95
- Data Source
  KAKENHI-PROJECT-24890041
[Presentation] 34.Japanese education system on health and health-associated knowledge evaluation scale for adolescence-pilot study.2022
- Author(s)
  Sunohara M, Yanagimoto S.
- Organizer
  American College Health Association Annual Meeting 2022.
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K13150
[Presentation] 大学生のヘルスリテラシーの特徴2022
- Author(s)
  春原光宏,立石晶子,江本範子,柳元伸太郎
- Organizer
  第2回日本ヘルスリテラシー学会学術集会
- Data Source
  KAKENHI-PROJECT-18K13150
[Presentation] 大学生の健康にかかわる知識の特徴2022
- Author(s)
  春原光宏,立石晶子,江本範子,柳元伸太郎
- Organizer
  第60回全国大学保健管理研究集会
- Data Source
  KAKENHI-PROJECT-18K13150
[Presentation] apanese education system on health and health-associated knowledge evaluation scale for adolescence-pilot study2022
- Author(s)
  春原光宏　柳元伸太郎
- Organizer
  American College Health Association (ACHA) 2022 annual meeting
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K13150
[Presentation] Can lung cancer with overexpression of RET-proto oncogene be a good candidate for vandetanib treatment?2014
- Author(s)
  Mitsuhiro Sunohara, Shigeki Morita, Masanori Kawakami, Kousuke Watanabe, Hidenori Kage, Yousuke Amano, Rie Ishikawa, Masahisa Fukayama, Takahide Nagase, Nobuya Ohishi, and Daiya Takai
- Organizer
  AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer
- Place of Presentation
  San Diego
- Data Source
  KAKENHI-PROJECT-24890041
[Presentation] Abstract B22: Can lung cancer with overexpression of RET-proto oncogene be a good candidate for vandetanib treatment?2014
- Author(s)
  Sunohara M, Morita S, Kawakami M, Watanabe K, Kage H, Amano Y, Ishikawa R, Fukayama M, Nagase T, Ohishi N, and Takai D
- Organizer
  AACR-IASLC Joint Conference on the Molecular Origins of Lung Cancer2014
- Data Source
  KAKENHI-PROJECT-24890041
[Presentation] Vandetanib can overcome the aquired resistance to gefitinib due to RET overexpression in lung cancer2012
- Author(s)
  春原光宏
- Organizer
  the 24th EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer Therapeutics’
- Place of Presentation
  Dublin, Ireland
- Data Source
  KAKENHI-PROJECT-24890041
[Presentation] Vandetanib can overcome the acquired resistance to gefitinib due to RET overexpression in lung cancer2012
- Author(s)
  Sunohara M, Kawakami M, Watanabe K, Morita S, Kage H, Amano Y, Fukayama M, Nagase T, Ohishi N, Takai D
- Organizer
  AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Data Source
  KAKENHI-PROJECT-24890041

SUNOHARA Mitsuhiro 春原 光宏

春原 光宏 スノハラ ミツヒロ

Sunohara Mitsuhiro 春原 光宏

Research Projects

Research Products

青少年の医学関連知識・ヘルスリテラシーの向上を目指した介入研究Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Scale development for medicine-associated knowledge for adolescence and health literacy evaluationPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

RET overexpression on lung cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Abstract B22: Can lung cancer with overexpression of RET-proto oncogene be a good candidate for vandetanib treatment?2014

Author(s)

Journal Title

Data Source

[Journal Article] Can lung cancer with overexpression of RET-proto oncogene be a good candidate for vandetanib treatment?2014

Author(s)

Journal Title

Data Source

[Journal Article] Vandetanib Can Overcome the Acquired Resistance to Gefitinib Due to RET Overexpression in Lung Cancer2012

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Vandetanib Can Overcome the Acquired Resistance to Gefitinib Due to RET Overexpression in Lung Cancer2012

Author(s)

Journal Title

Data Source

[Presentation] 34.Japanese education system on health and health-associated knowledge evaluation scale for adolescence-pilot study.2022

Author(s)

Organizer

Data Source

[Presentation] 大学生のヘルスリテラシーの特徴2022

Author(s)

Organizer

Data Source

[Presentation] 大学生の健康にかかわる知識の特徴2022

Author(s)

Organizer

Data Source

[Presentation] apanese education system on health and health-associated knowledge evaluation scale for adolescence-pilot study2022

Author(s)

Organizer

Data Source

[Presentation] Can lung cancer with overexpression of RET-proto oncogene be a good candidate for vandetanib treatment?2014

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] Abstract B22: Can lung cancer with overexpression of RET-proto oncogene be a good candidate for vandetanib treatment?2014

Author(s)

Organizer

Data Source

[Presentation] Vandetanib can overcome the aquired resistance to gefitinib due to RET overexpression in lung cancer2012

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] Vandetanib can overcome the acquired resistance to gefitinib due to RET overexpression in lung cancer2012

Author(s)

Organizer

Data Source

SUNOHARA Mitsuhiro 春原光宏

春原光宏スノハラミツヒロ

Sunohara Mitsuhiro 春原光宏